ArticleFrontiers in pharmacology2018
Synergistic Killing of Polymyxin B in Combination With the Antineoplastic Drug Mitotane Against Polymyxin-Susceptible and -Resistant
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Deciphering synergistic killing mechanisms of capsaicin combined with colistin against colistin-resistantBiochemistry and biophysics reports · 2026Article
- Adaptive survival strategies of Acinetobacter baumannii under different classes of antibiotic stress revealed through transcriptomic profiling.Archives of microbiology · 2026Article
- Breaking the resistance: integrative approaches with novel therapeutics against Klebsiella pneumoniae.Archives of microbiology · 2024Review
- Drug Repurposing Approaches towards Defeating Multidrug-Resistant Gram-Negative Pathogens: Novel Polymyxin/Non-Antibiotic Combinations.Pathogens (Basel, Switzerland) · 2022Review
- Mechanisms Underlying Synergistic Killing of Polymyxin B in Combination with Cannabidiol againstPharmaceutics · 2022Article
- Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Unique mechanistic insights into pathways associated with the synergistic activity of polymyxin B and caspofungin against multidrug-resistantComputational and structural biotechnology journal · 2022Article
- Comparative metabolomics reveals key pathways associated with the synergistic activity of polymyxin B and rifampicin combination against multidrug-resistant Acinetobacter baumannii.Biochemical pharmacology · 2021Article
- New Insights Into the Antibacterial Mechanism of Cryptotanshinone, a Representative Diterpenoid Quinone FromFrontiers in microbiology · 2021Article
- Metabolomic Description of Ivacaftor Elevating Polymyxin B Mediated Antibacterial Activity in Cystic FibrosisACS pharmacology & translational science · 2020Article
- Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens.Computational and structural biotechnology journal · 2020Article
- Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant Klebsiella pneumoniae.Antimicrobial agents and chemotherapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Polymyxins are currently used as the last-resort antibiotics against multidrug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.